G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

It seems like no matter what I do, I can’t lose weight. Most of my family members struggle with their weight too. Do our ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Scientists have discovered a naturally-occurring molecule that rivals the weight-loss effects of semaglutide-based GLP-1s like Ozempic in animals.

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.